Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Editas Medicine
(NQ:
EDIT
)
5.620
-0.270 (-4.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Via
Benzinga
Why Editas Medicine's Shares Are Falling Thursday
November 17, 2022
The company shelved a clinical trial for one of its lead therapies.
Via
The Motley Fool
Editas Medicine: Q3 Earnings Insights
November 02, 2022
Editas Medicine (NASDAQ:EDIT) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Editas Medicine's Return On Capital Employed Insights
August 10, 2022
Via
Benzinga
Editas Medicine: Q2 Earnings Insights
August 03, 2022
Editas Medicine (NASDAQ:EDIT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings
November 17, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday.
Via
Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
November 17, 2022
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67...
Via
Benzinga
Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder
November 17, 2022
Via
Benzinga
BMO Initiates Coverage On This Gene Editing Spearhead
June 17, 2022
Via
Benzinga
Expert Ratings for Editas Medicine
May 09, 2022
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Editas Medicine: Q1 Earnings Insights
May 04, 2022
Editas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 17, 2022
Via
Benzinga
S&P 500 Down 1%; Crude Oil Drops Sharply
November 17, 2022
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday.
Via
Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
November 17, 2022
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 17, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About Editas Medicine
November 03, 2022
Over the past 3 months, 5 analysts have published their opinion on Editas Medicine (NASDAQ:EDIT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
September 29, 2022
Upgrades
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch.
Via
InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
June 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 07, 2022
Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
16 Stocks Moving in Tuesday's Pre-Market Session
June 07, 2022
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares rose 38% to $1.27 in pre-market trading following a Form 4 filing showing the purchase of 2,044,676 shares by CEO Salvatore Palella at an average price of...
Via
Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
June 02, 2022
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Via
InvestorPlace
Editas Medicine's Return On Capital Employed Insights
May 19, 2022
Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.
Via
Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 28, 2022
Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to...
Via
Benzinga
Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia
April 26, 2022
The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia from leading...
Via
Benzinga
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents
March 01, 2022
The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.